سعر جلوكوفاج 500 مجم 50 قرص 2024

Glucophage 500mg 50 f.c.tab — Metformin (Mina Pharm).

• Treatment of type 2 diabetes mellitus, particularly in overweight patients, when diet and exercise alone do not give adequate glycaemic control. Adults: monotherapy or combination with other oral antidiabetics or insulin. Children from 10 years: monotherapy or with insulin.Population: Adults and children ≥10 yearsUK eMC / MHRA

• Very common at start: GI symptoms (nausea, vomiting, diarrhoea, abdominal pain, anorexia). Common: vitamin B12 decrease, taste disturbance. Very rare: lactic acidosis; hepatitis/LFT changes; skin reactions.International label, same formulation · UK eMC / MHRA

• Hypersensitivity to metformin/excipients; acute metabolic acidosis (incl. lactic acidosis, DKA); diabetic pre-coma; severe renal failure (GFR <30 mL/min); acute conditions altering renal function; diseases causing tissue hypoxia (acute); hepatic insufficiency; acute alcohol intoxication; alcoholism.International label, same formulation · UK eMC / MHRA

• Risk of lactic acidosis with acute renal worsening, cardiorespiratory illness or sepsis. Temporarily stop in dehydration. Assess GFR before start and regularly. Stop for iodinated contrast (≥48 h restart if renal function stable). Stop for major surgery under anaesthesia. May lower vitamin B12.International label, same formulation · UK eMC / MHRA

• AlcoholMajorAlcohol intoxication increases lactic acidosis risk (especially fasting/malnutrition/hepatic impairment); concomitant use not recommended.UK eMC / MHRA

• Large pregnancy data do not indicate increased congenital abnormality risk with metformin. If clinically needed, metformin may be considered in pregnancy/periconception as add-on or alternative to insulin. Maintain near-normal glycaemia.International label, same formulation · UK eMC / MHRA
• Metformin excreted in breast milk; limited data show no adverse effects in infants; breast-feeding not recommended during treatment — weigh benefit vs risk.International label, same formulation · UK eMC / MHRA

• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).